The idiopathic pulmonary fibrosis (IPF) market has witnessed a number of emerging trends such as licensing agreements, alliances and acquisitions between the key vendors functioning in the market, with Merck being the latest beneficiary in the race, according to a report by GlobalData.

Titled ‘Idiopathic Pulmonary Fibrosis-Opportunity Analysis and Forecast to 2025‘, the report says that acquisitions, such as that of Genentech by Roche and Promedior by Bristol-Myers Squibb, have been a key strategy followed by the companies since 2014 to hit the IPF market.

Merck will be a new contender to enter the IPF market, which is currently dominated by Roche’s Esbriet and Boehringer Ingelheim’s Ofev, both with a premium price of more than $90,000 a year.

Through its subsidiary, Merck will acquire Afferent Pharmaceuticals’ lead candidate AF-219 (candidate in phase II trials in IPF patients) and all outstanding stocks of the company for a purchase consideration of $500m, following the same inorganic strategy.

“Through its subsidiary, Merck will acquire Afferent Pharmaceuticals’ lead candidate AF-219 … and all outstanding stocks of the company for a purchase consideration of $500m.”

The acquisition of orally administered P2X3 selective, non-narcotic drug candidate AF-219 will provide Merck with an opportunity to gain from the anticipated growth in the IPF market, which is forecast to reach $3.2bn by 2025, according to Mathew Thaxter, GlobalData’s Analyst covering immunology.

However, Thaxter adds that AF-219, despite having competitive advantage over the other two drugs in alleviating disease-related symptoms such as chronic cough, will have limited benefit as it doesn’t stop or hinder disease progression.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This is the reason it is unlikely to command high-price premiums that Esbriet and Ofev enjoy, says the analyst, who further adds that the drug will still benefit from a large base of 107,000 IPF-diagnosed patients aged 50 or above in the seven major markets of the US, Germany, France, Spain, Italy, the UK and Japan.

The low price is expected to be offset by the large patient base, while more sales are expected upon receiving regulatory approval.